Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia

  • Authors:
    • Haiwu Cao
    • Xiaohong Zhao
    • Shiyun Lu
    • Zhi Wang
  • View Affiliations

  • Published online on: April 30, 2018     https://doi.org/10.3892/etm.2018.6111
  • Pages: 5431-5435
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the current study was to measure the expression of acetyl‑N‑Ser‑Asp‑Lys‑Pro (ACSDKP) in patients with acute myeloid leukemia (AML) and the effect of prolyl oligopeptidase inhibitor (POPi) on the bone marrow stromal cells of these patients. Serum and bone marrow stromal cell samples were collected from 33 patients with AML admitted to Wuxi Second People's Hospital, Nanjing Medical University between September 2011 and August 2016. ACSDKP levels were measured using a highly specific competitive enzyme immunoassay (EIA). Bone marrow stromal cells were treated with synthetic ACSDKP (10 µM/ml) or different concentrations of POPi S17092 (25, 50 and 100 µg/ml). Cells that received no treatment were used as control. An MTT assay was conducted to measure the proliferation of bone marrow stromal cells. The results demonstrated that serum levels of ACSDKP in patients with AML were significantly higher than those of controls (P<0.05). Following treatment with ACSDKP, cell proliferation was significantly increased compared with untreated cells (P<0.05). However, following treatment with different concentrations of POPi, the expression of ACSDKP was significantly decreased in a dose‑dependent manner (P<0.05). Furthermore, the proliferation of bone marrow stromal cells was also decreased in a dose‑dependent manner. Therefore, the present study demonstrated that ACSDKP levels were increased in the serum and bone marrow stromal cells of patients with AML and that ACSDKP promoted the proliferation of bone marrow stromal cells of these patients, which was inhibited by POPi. These results may identify a novel target for the treatment of AML.
View Figures
View References

Related Articles

Journal Cover

June-2018
Volume 15 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cao H, Zhao X, Lu S and Wang Z: Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia. Exp Ther Med 15: 5431-5435, 2018
APA
Cao, H., Zhao, X., Lu, S., & Wang, Z. (2018). Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia. Experimental and Therapeutic Medicine, 15, 5431-5435. https://doi.org/10.3892/etm.2018.6111
MLA
Cao, H., Zhao, X., Lu, S., Wang, Z."Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia". Experimental and Therapeutic Medicine 15.6 (2018): 5431-5435.
Chicago
Cao, H., Zhao, X., Lu, S., Wang, Z."Prolyl oligopeptidase inhibitor suppresses the upregulation of ACSDKP in patients with acute myeloid leukemia". Experimental and Therapeutic Medicine 15, no. 6 (2018): 5431-5435. https://doi.org/10.3892/etm.2018.6111